The European Hematology Association 2022 Hybrid Congress (EHA2022)

Vienna, Austria 09 June 2022 - 12 June 2022

Pegcetacoplan bests SoC for PNH in PRINCE update

19 Jul 2022 by

Treatment with pegcetacoplan improves the quality of life (QoL) of patients with paroxysmal nocturnal haemoglobinuria (PNH) who were naïve to complement inhibitor therapy, according to the PRINCE study update presented at EHA 2022. This comes with the added benefit of disease control.

Pegcetacoplan bests SoC for PNH in PRINCE update

19 Jul 2022

Second-line axi-cel improves EFS in elderly patients with R/R LBCL

16 Jul 2022 by

Second-line treatment with the CAR* T-cell therapy axicabtagene ciloleucel (axi-cel) led to significantly longer event-free survival (EFS) in patients aged ≥65 years with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) compared with standard of care (SoC), according to a preplanned subgroup analysis of the ZUMA-7** trial presented at EHA 2022.

Second-line axi-cel improves EFS in elderly patients with R/R LBCL

16 Jul 2022

Venetoclax-obinutuzumab ± ibrutinib induces PFS benefit in CLL

13 Jul 2022 by

A time-limited regimen of venetoclax plus obinutuzumab with or without ibrutinib improved progression-free survival (PFS) in fit, treatment-naïve patients with chronic lymphocytic leukaemia (CLL), according to results of the phase III GAIA/CLL13 trial presented at EHA 2022.

Venetoclax-obinutuzumab ± ibrutinib induces PFS benefit in CLL

13 Jul 2022

Quizartinib bounces back, doubles OS in FLT3-ITD-positive AML

09 Jul 2022 by

The oral FLT3 inhibitor quizartinib more than doubled overall survival (OS) when added to first-line chemotherapy in patients with newly diagnosed FLT3-ITD*-positive acute myeloid leukaemia (AML) in the phase III QuANTUM-First** trial

Quizartinib bounces back, doubles OS in FLT3-ITD-positive AML

09 Jul 2022

Age the biggest risk factor for COVID-19 mortality in haematological cancer patients

07 Jul 2022 by

A study conducted in England has shown that in patients with haematological malignancy, the risk of COVID-19–related mortality is greatly influenced by age.

Age the biggest risk factor for COVID-19 mortality in haematological cancer patients

07 Jul 2022

Post-transplant KRd a new SoC for MM?

07 Jul 2022 by

In the ongoing phase III ATLAS study evaluating patients with newly diagnosed multiple myeloma (MM), progression-free survival (PFS) was better with maintenance treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) than lenalidomide (R) alone after autologous stem-cell transplantation (ASCT).

Post-transplant KRd a new SoC for MM?

07 Jul 2022

Longer luspatercept treatment continues to benefit TDT patients

06 Jul 2022 by

Patients with transfusion-dependent β-thalassemia (TDT) continued to benefit from over 3 years of treatment with luspatercept, a first-in-class erythroid maturation agent that enhances late-stage erythropoiesis, according to the longer-term efficacy analysis of the phase III BELIEVE study.

Longer luspatercept treatment continues to benefit TDT patients

06 Jul 2022

Long-term data show sustained benefit of sutimlimab for CAD

05 Jul 2022 by

The final 2-year (part B) results of the phase III CARDINAL study continued to demonstrate the favourable risk-benefit profile of sutimlimab, a first-in-class selective anti-C1s classical complement pathway (CP) inhibitor, for the management of cold agglutinin disease (CAD), a rare chronic, autoimmune haemolytic anaemia characterized by classical CP-mediated haemolysis.

Long-term data show sustained benefit of sutimlimab for CAD

05 Jul 2022

Decitabine as good as, but safer than, chemo in AML

01 Jul 2022 by

Extended treatment with decitabine is as good as, but safer than, standard induction chemotherapy (IC) in older patients with acute myeloid leukaemia (AML), according to a phase III study presented at EHA 2022.

Decitabine as good as, but safer than, chemo in AML

01 Jul 2022

Updated ASCEMBL results boost asciminib potential for CML

28 Jun 2022 by

In the week-96 analysis of the phase III ASCEMBL trial, the first BCR::ABL1 STAMP* inhibitor asciminib sustained superiority over bosutinib for individuals with CML-CP** who have failed ≥2 lines of prior tyrosine kinase inhibitors (TKIs).

Updated ASCEMBL results boost asciminib potential for CML

28 Jun 2022